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Abstract
Membrane transporters play crucial roles in the cellular uptake and efflux of an array of small molecules including nutrients,
environmental toxins, and many clinically used drugs. We hypothesized that common genetic variation in the proximal
promoter regions of transporter genes contribute to observed variation in drug response. A total of 579 polymorphisms
were identified in the proximal promoters (2250 to +50 bp) and flanking 59 sequence of 107 transporters in the ATP
Binding Cassette (ABC) and Solute Carrier (SLC) superfamilies in 272 DNA samples from ethnically diverse populations. Many
transporter promoters contained multiple common polymorphisms. Using a sliding window analysis, we observed that, on
average, nucleotide diversity (p) was lowest at approximately 300 bp upstream of the transcription start site, suggesting
that this region may harbor important functional elements. The proximal promoters of transporters that were highly
expressed in the liver had greater nucleotide diversity than those that were highly expressed in the kidney consistent with
greater negative selective pressure on the promoters of kidney transporters. Twenty-one promoters were evaluated for
activity using reporter assays. Greater nucleotide diversity was observed in promoters with strong activity compared to
promoters with weak activity, suggesting that weak promoters are under more negative selective pressure than promoters
with high activity. Collectively, these results suggest that the proximal promoter region of membrane transporters is rich in
variation and that variants in these regions may play a role in interindividual variation in drug disposition and response.
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Introduction
Membrane transporters facilitate the uptake and efflux of
endogenous compounds, ions, and drugs across cellular mem-
branes. Two major superfamilies, the ATP binding cassette (ABC)
and solute carrier (SLC) families, are recognized as important for
the transport of drugs and other xenobiotics. ABC transporters are
efflux pumps that rely on ATP hydrolysis to actively move
substrates across biological membranes [1,2]. In the ABC
transporter superfamily, drug transport has primarily been
associated with P-glycoprotein (ABCB1), Breast Cancer Resistance
Protein (BCRP/ABCG2), and several members of the Multidrug-
Resistance Associated Protein (MRP/ABCC) family. These
transporters act to limit the access of drugs to protected tissue
compartments, and to eliminate drugs and metabolites via bile and
urine [3,4]. Members of the SLC superfamily generally mediate
the cellular uptake of nutrients such as glucose and amino acids,
either through a facilitative transport mechanism where the
substrate is translocated down its concentration gradient, or
through secondary active transport mechanisms, where substrate
translocation against a concentration gradient is coupled to ion
flux along the cell membrane electrochemical gradient [5]. Like
the ABC transporters, SLC transporters from a number of families
accept a variety of structurally diverse drugs as substrates [6].
Variation at transporter gene loci may be responsible for
differences in the therapeutic and adverse responses to pharmaceu-
ticals [7–9]. The coding regions of many membrane transporters
have been sequenced to locate polymorphisms that alter the
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number and minor allele frequencies of non-synonymous polymor-
phisms in membrane transporters exons are generally small [10]. In
contrast, in non-coding regions, polymorphisms are more abundant
and minor allele frequencies are higher due to the lower selection
pressure on these regions. Because of the generally lower genetic
constraint in the regulatory regions of membrane transporters, we
hypothesize that these regions may contain most of the common
variation that underlies variable drug response. The proximal
promoter has been defined as the region immediately surrounding
the transcriptional start site, which is critical in binding polymerase
complexes necessary for gene transcription [11,12]. Polymorphisms
in the proximal promoter may alter the rate of transcription
resulting in changes in gene expression, thereby ultimately affecting
the level of cellular uptake or efflux. Polymorphisms that alter the
expression levels of membrane transporters could determine the
effective dosage of a drug by altering the systemic or tissue specific
exposure to the drug. Some polymorphisms in the proximal
promoter of membrane transporter genes identified in this
sequencing effort have been shown to alter transcription rates in
reporter assays and associate with expression levels in human
lymphoblastoid cell lines [13,14].
To facilitate the discovery of variants that may influence drug
transporter expression levels, we sequenced the proximal promot-
ers (2250 bp upstream to 50 bp downstream of the transcription
start site) [15] of 107 transporters including 42 ABC and 65 SLC
membrane transporter genes (Table S1). To identify both common
and rare variants we used a large sample consisting of DNA from
272 individuals from four populations. The level of variation in the
proximal promoters of membrane transporters was compared to
other gene regions. Using population genetic parameters, we
compared variation among transporter families and superfamilies,
and in transporters expressed primarily in the liver versus those
expressed primarily in the kidney. We experimentally determined
promoter activity using reporter assays and compared variation in
strong and weak promoters. These data will contribute to the
characterization of non-coding polymorphisms on the gene
expression of membrane transporters.
Results
Polymorphism Discovery
New polymorphisms identified. A total of 52,445 base
pairs were sequenced, and 579 polymorphisms (out of which 207
were singletons) were observed (Table 1). Single nucleotide
polymorphisms (SNPs) were the most common type of
polymorphism (93.6%). Cross-reference of our variants to the
dbSNP database indicated that 369 polymorphisms were novel
(dbSNP build 129) (Table S2). Of these novel variants, 54 had
minor allele frequencies greater than 5% in at least one
population.
The sequenced range covered 31,715 base pairs in proximal
promoters and 20,730 base pairs of non-coding sequence
upstream of the proximal promoters. In total, 373 polymorphisms
were observed in the proximal promoters and 206 in the 59
flanking regions. The observed frequency of polymorphisms in the
59 flanking regions (1/101 bp) was thus comparable to our
previous findings in non-coding intronic regions in 24 transporters
(1/118 bp) [10]. The proximal promoter regions (1/85) were more
polymorphic than the intronic and 59 flanking regions (Table 1).
Allele frequencies of polymorphisms. The number of
polymorphisms per proximal promoter ranged from zero to
fourteen, with the majority of transporters (90%) having at least
one common (MAF$5%) polymorphism or multiple singletons in
this region. Only 10% of promoters had no polymorphisms or only
one singleton. The maximum number of singletons in any
promoter was four. Common polymorphisms with MAF.5% in
at least one population were found in 66% of proximal promoters.
Interestingly, a large number of polymorphisms were found at a
frequency of 20% or greater (Figure 1), which is in distinct contrast
to polymorphisms found in coding regions of membrane
transporters [10]. Transporters with the highest number of
polymorphisms in their proximal promoter were SLC7A5, which
transports large neutral amino acids; SLC47A1, which transports
endogenous and exogenous organic cations; ABCC5, which
exports cyclic nucleotides; ABCD4, involved in the transport of
fatty acids; SLC22A5 and SLC22A16, organic anion/cation
Table 1. Summary of variation in membrane transporter promoters.
Base Pairs SNPs MAF ,1% SNPs MAF$1% Indels Total
nP P 5 9 PP 59 PP 59 PP 59 Total
All Genes 107 31715 20730 133 74 214 121 26 11 579
All ABC 42 12464 9952 45 17 65 48 8 6 189
ABCA 9 2667 2140 13 2 13 7 3 1 39
ABCB 10 2987 1895 5 2 19 7 3 2 38
ABCC 11 3251 3054 12 6 12 14 1 2 47
ABCG 5 1500 1215 8 5 8 11 1 1 34
Other ABC 7 2059 1648 7 2 13 9 0 0 31
All SLC 65 19251 10778 88 57 149 73 18 5 390
SLC6 13 3889 2900 17 14 40 19 1 0 91
SLC17 6 1713 1074 9 9 9 2 0 2 31
SLC22 17 5037 1983 24 9 33 7 6 0 79
SLC28/29 6 1800 1238 10 2 15 12 1 0 40
SLCO 7 2100 945 8 4 11 3 3 2 31
Other SLC 16 4712 2638 20 19 41 30 7 1 118
MAF: Minor allele frequency, PP: proximal promoter.
doi:10.1371/journal.pone.0006942.t001
ABC/SLC Promoter Polymorphisms
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cancer and anti-viral drugs; SLC17A3, a phosphate transporter
located in the endoplasmic reticulum membrane; SLC15A1,
involved in the intestinal absorption and renal disposition of di-
and tripeptides; and the sodium neurotransmitter symporters
SLC6A4, SLC6A12, SLC6A17, and SLC6A19 (Table S3).
Population specificity of polymorphisms. The expected
distributions of polymorphisms were observed in the four
examined populations. In particular, a larger number of
singletons and low frequency polymorphisms were observed in
the African American population than in the other three
populations (Figure 1) and the overall number of polymorphisms
in African Americans was also higher than for any other
population. However, 36% of the polymorphisms were not
observed in the African American population and thus the
addition of multiple populations contributed greatly to the
magnitude of variation identified in the total sample (Table 2).
Insertions and Deletions. Thirty-seven of the
polymorphisms identified were insertions or deletions (indels).
The ratio of 37 indels to 537 SNPs (ca. 0.07) was similar to what
was previously observed in intronic regions of ABC and SLC
transporters (21 indels/350 SNPs or 0.06) [10]. Importantly the
indel to SNP ratio in promoter regions was substantially greater
than that observed in coding regions of ABC and SLC transporters
(8 indels/330 SNPs or 0.02). These results suggest that insertion
and deletion events, which may involve genomic rearrangement
and recombination, are more likely in the upstream region than in
the coding regions of genes. This observation is expected because
indels in coding regions can lead to frameshift mutations, which
result in a truncated protein that may be hyper-, hypo-, or
neomophic explaining the high negative selective pressure in
coding regions.
A greater number of indels per bp sequenced was observed in
the proximal promoters (1/1220) than in the 59 flanking regions
(1/1885 bp). The type of indel also differed between proximal
promoters and the 59 flanking sequence. Single base pair indels
made up a greater percentage of the total indels in the 59 flanking
regions (91%) than in the proximal promoters (27%). It has been
reported that a majority of indel sequences in the human genome
are AT rich [16]. However, in the proximal promoters in our
dataset, a majority (62%) of the indel sequences were instead GC
rich. This is consistent with the observation that a large proportion
of mammalian promoters contain CpG islands [12,17]. Most
indels identified in this sequencing effort were flanked by identical
sequence. This was true for both single bp indels that have at least
one base pair of the same identity next to the insertion or deletion
site (91%), and for multibase indels that have the identical complex
sequence flanking the indel (54%). This leads to ambiguity in the
exact location of the indel. The flanking sequence for all indels can
be viewed at http://pharmacogenetics.ucsf.edu/ and Table S2).
Haplotypes. Strong linkage disequilibrium between
polymorphisms in the 300 bp proximal promoter region was
observed in all populations, as would be expected due to their
proximity (Table S4). In general, when the minor alleles of
polymorphisms were present in multiple populations, they also
formed the same haplotypes in all populations. In most cases the
minor allele of each polymorphism was in a haplotype that did not
include the minor allele of any other polymorphism. Unexpectedly
there was more haplotype diversity in SLC22A5 in the Chinese
population than in any other population. The Chinese samples
had four common haplotypes that differed from the reference
haplotype, whereas the other three populations had only two
haplotypes with frequencies above 2%. This may be related to a
Chinese specific fixation of the minor allele of a SNP just
downstream of the proximal promoter, which is present on all four
common haplotypes.
Polymorphisms in ABC and SLC superfamilies. The two
transporter superfamilies differed in the amount of genetic
diversity observed. More polymorphisms were observed in the
SLC promoters than in the ABC promoters, with both common
and rare polymorphisms contributing to this observation. (Table 1)
Figure 1. Ethnic breakdown of proximal promoter SNPs. The
number of SNPs present in each ethnic group are represented by
shaded bars: African Americans (black), European Americans (dark grey),
Mexican Americans (light grey), and Asian Americans (white). SNPs are
categorized based on the minor allele frequency (MAF) occurring in
each corresponding ethnic group.
doi:10.1371/journal.pone.0006942.g001
Table 2. Proximal promoter SNPs shared among 4 major
ethnic groups.
Ethnic Groups
AA EA ME AS # of SNPs % of Total SNPs
x9 0 2 6 . 0
x 30 8.6
x 33 9.5
x4 2 1 2 . 1
x x 7 2.0
x x 17 4.9
x x 2 0.6
x x 8 2.3
x x 5 1.4
xx5 1 . 4
x x x 24 6.9
x x x 4 1.2
xxx1 0 . 3
x xx1 0 . 3
x xxx7 8 2 2 . 5
223 157 167 138 347
AA: African American; EA: European American; ME: Mexican American; AS: Asian
American.
doi:10.1371/journal.pone.0006942.t002
ABC/SLC Promoter Polymorphisms
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ABC transporter proximal promoters and every 75 base pairs in
SLC transporters. Correspondingly, the fraction of transporters
that had no polymorphisms or only one singleton in the proximal
promoter was greater in the ABC (14%) than in the SLC
superfamily (8%). This trend was also observed for polymorphisms
with minor allele frequencies greater than 5%. That is, a lower
percentage of ABC promoters (57%) had at least one
polymorphism with a MAF.5% in at least one population
compared to SLC promoters (72%).
Population Genetics of Transporter Promoters
Population genetic statistics. Genetic variation in exons is
constrained by negative selection [10,18,19]. To determine if this
was also the case for the proximal promoter regions we calculated
the population genetic parameters p (nucleotide diversity/average
heterozygosity) and h (the population mutation parameter) for
each promoter, as well as two estimates of selection pressure:
Tajima’s D and Fay and Wu’s H statistics (Tables 3, 4 and S3).
Proximal promoters in membrane transporters appear to be
characterized by greater genetic variation than coding regions of
these genes. In particular, a h of 15 and a p of 9.6 were calculated
for 102 proximal promoters (Table 3). These values are greater
than the values of 8.9 and 4.0 observed previously for h and p in
the coding region of 24 membrane transporters [10]. These data
suggest that variations in promoters are less deleterious than in
exons, which have much less heterozygosity. Consistent with the
greater number of polymorphisms observed in the SLC than in the
ABC family, the values of p and h in both the proximal promoters
and 59 upstream flanking sequence were higher in SLC
transporters (Table 3). Values of p were also higher in many
protein domains in the SLC transporters than in the ABC
transporters [10]. These data suggest that in general, SLC
transporters can tolerate more variation than ABC transporters,
possibly due to functional redundancies within many SLC
subfamilies. The trends for p and h were similar in all of the
populations (Table 3).
Regional differences in nucleotide diversity. On average,
more variation was observed in the proximal promoter regions
than in the 59 flanking sequence (Table 1 and 3). To get a more
detailed view of the regional differences, we used a sliding window
approach to determine local nucleotide diversity in ABC and SLC
transporters in each of the examined populations (Fig. 2). In the
ABC transporters, both h and p were at a maximum in a range
centered around 150 bp upstream from the transcription start site.
A similar peak in nucleotide diversity was also observed in the SLC
transporters, but in contrast to the ABCs, these transporters also
showed a sharply increased variability further upstream. Common
to both families was a minimum diversity centered around 250 bp
upstream from the transcription start site.
Positive and negative selection. Though variation in most
promoters was consistent with the infinite sites neutral model [20],
some ABC and SLC transporters showed signs of positive selection
(Table 4). The observation of positive selection is consistent with
previous findings of positive selection in promoters of other genes
[21,22]. The proximal promoters of many transporters appear to
have similar pressures acting on them in more than one
population. ABCD2 and ABCD4 both involved in the transport
of fatty acids, and SLCO1A2, which mediates cellular uptake of
organic ions such as bile acids and steroidal compounds, appeared
to have the greatest degree of positive selection as indicated by the
low H values in all four populations (Table 4). Other transporters
that showed some degree of positive selection in several
populations include SLC19A2, a vitamin B1 transporter, the
sodium neurotransmitter symporters SLC6A4 and SLC6A14, and
some ABC transporters involved in multidrug resistance, (ABCB9,
ABCC3 and ABCC9). In contrast to these data showing positive
selection, ABCA13, which encodes the largest ABC transporter
with 5,058 amino acids [23], had significantly positive H values in
two populations consistent with purifying or negative selection
Table 3. Summary of population genetics statistics of membrane transporter promoters.
h x1 0 4 h x1 0 4 h x1 0 4 p x1 0 4 p x1 0 4 p x1 0 4
Pop. PP 59 Total PP 59 Total
All Genes AA 12.1 6 2.9 9.2 6 2.4 11.0 6 2.6 10.1 6 4.9 6.9 6 3.5 8.9 6 4.3
(n=102) EA 8.2 6 2.0 5.4 6 1.5 7.2 6 1.8 8.8 6 4.3 4.9 6 2.5 7.3 6 3.6
ME 9.3 6 2.3 6.8 6 1.8 8.4 6 2.0 8.4 6 4.1 5.0 6 2.6 7.1 6 3.5
AS 7.6 6 1.9 5.6 6 1.5 6.8 6 1.7 8.2 6 4.0 5.2 6 2.7 7.1 6 3.4
Total 15.3 6 3.0 11.4 6 2.3 13.9 6 2.7 9.6 6 4.6 5.9 6 3.0 8.2 6 4.0
All ABC AA 10.1 6 2.6 7.5 6 2.1 8.9 6 2.3 9.1 6 4.6 5.5 6 3.0 7.5 6 3.7
(n=41) EA 6.3 6 1.8 3.5 6 1.1 5.0 6 1.3 7.8 6 4.0 3.7 6 2.1 6.0 6 3.0
ME 8.2 6 2.2 4.8 6 1.5 6.7 6 1.7 7.9 6 4.0 3.7 6 2.1 6.0 6 3.0
AS 7.0 6 1.9 4.0 6 1.3 5.7 6 1.5 7.7 6 3.9 3.6 6 2.0 5.9 6 2.9
Total 12.8 6 2.7 8.0 6 1.8 10.7 6 2.2 8.8 6 4.4 4.4 6 2.4 6.8 6 3.4
All SLC AA 13.4 6 3.3 11.3 6 3.1 12.7 6 3.1 10.8 6 5.3 8.7 6 4.5 10.1 6 4.9
(n=61) EA 9.6 6 2.4 7.7 6 2.2 9.0 6 2.2 9.5 6 4.7 6.4 6 3.4 8.5 6 4.2
ME 10.1 6 2.6 9.3 6 2.6 9.8 6 2.4 8.8 6 4.4 6.5 6 3.5 8.1 6 4.0
AS 8.0 6 2.1 7.5 6 2.2 7.8 6 2.0 8.5 6 4.2 7.2 6 3.8 8.1 6 4.0
Total 17.0 6 3.4 15.5 6 3.3 16.5 6 3.2 10.1 6 5.0 7.7 6 4.0 9.4 6 4.6
AA: African American; EA: European American; ME: Mexican American; AS: Asian American. Pop: population, PP: proximal promoter.
doi:10.1371/journal.pone.0006942.t003
ABC/SLC Promoter Polymorphisms
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sites, neutral model.
Relationship Between Genetic Variation and Promoter
Activity
Variation in hepatic and renal transporters. Because
many of the transporters analyzed in this study play a role in hepatic
and renal drug elimination, we compared genetic variation in liver
and kidney transporters. Transporters were classified as having
significant expression in liver or kidney (or both) if their expression
levels ranked in the top third of expressed genes in multiple sources
of microarray data [24–27] or they showed significant expression in
RT-PCR experiments [28]. The transporters classified as being
expressed in the kidney, the liver, or in both tissues based on these
available datasets are presented in Table S5. We then determined
the nucleotide diversity for the transporters included in each of the
three groups. Transporters that were predominantly expressed in
the liver were found to have higher average heterozygosity than
transporters that were highly expressed in the kidney, and
transporters expressed at high levels in both tissues had the lowest
average heterozygosity (Figure 3 and Table S6).
Genetic variation in proximal promoters expressed in cell
lines
To confirm that the sequenced regions contain a functional
promoter, we cloned a subset of the sequenced regions into firefly
luciferase reporter constructs and expressed them in continuous
cell lines from gastrointestinal epithelia (JEG-3 and HCT-116),
kidney (ACHN), liver (HEPG2), pancreas (PANC-1) and glioblas-
toma (T98G). We selected 21 promoters of the two major
superfamilies, SLC and ABC membrane transporters that play
significant role in transporting drug molecules and xenobiotics into
or out of the cells. In addition, these selected groups of
transporters, such as organic cation transporters (SLC22A),
nucleoside transporters (SLC28A and SLC29A) and ABC
transporters have high expressions in liver and/or kidney tissues
where they play important roles in drugs/xenobiotics absorption,
distribution and elimination. Transcriptional activity of the most
common haplotype of each promoter is shown in Figure 4A. The
mean activity across all tested cell lines was significantly above the
negative control in 15 out of 21 promoters suggesting that the
majority of the cloned regions have measurable promoter activity
(Figure 4A). We designated promoters as having low, intermediate
Table 4. Positive selection in membrane transporter promoters.
H (Significance)
AA EA ME AS
ABC Transporters Significant in 4 Populations
ABCD2 23.56 (**) 23.79 (***) 23.86 (***) 23.81 (***)
ABCD4 25.09 (*) 25.52 (**) 25.21 (*) 25.54 (***)
Significant in 3 Populations
ABCB9 20.76 (n. s.) 22.31 (***) 22.10 (*) 22.73 (**)
ABCC3 20.89 (n. s.) 21.59 (*) 21.58 (*) 23.44 (**)
ABCC9 23.87 (***) 23.97 (***) 24.01 (***) n. a.
Significant in 2 Populations
ABCA4 20.66 (n. s.) n. a. 21.86 (*) 21.97 (**)
ABCD1 0.22 (n. s.) 21.55 (*) 21.35 (*) 21.34 (n. s.)
Total n transporters with
significant H
36 7 5
SLC Transporters Significant in 4 Populations
SLC19A2 21.97 (*) 22.76 (**) 22.49 (**) 21.81 (*)
SLCO1A2 25.72 (***) 25.84 (***) 25.08 (**) 25.00 (***)
SLC22A10 21.74 (*) 21.87 (*) 21.90 (*) 22.00 (***)
Significant in 3 Populations
SLC6A4 21.85 (**) 21.81 (n. s.) 21.82 (*) 21.91 (*)
SLC6A14 20.51 (n. s.) 21.62 (*) 21.59 (*) 21.94 (*)
SLC47A1 22.00 (*) 21.93 (n. s.) 22.01 (*) 22.01 (*)
SLCO1B1 21.74 (n. s.) 21.90 (*) 21.97 (*) 21.90 (*)
Significant in 2 Populations
SLC6A12 21.60 (n. s.) 21.81 (*) 21.66 (n. s.) 22.00 (***)
SLC15A1 21.20 (n. s.) 21.94 (*) n. a. 21.93 (**)
Significant in 1 Population
SLC18A1 20.96 (n. s.) 0.04 (n. s.) 20.41 (n. s.) 21.23 (*)
SLC22A12 21.51 (n. s.) 22.67 (*) 22.20 (n. s.) 21.53 (n. s.)
Total n transporters with
significant H
58 7 1 0
doi:10.1371/journal.pone.0006942.t004
ABC/SLC Promoter Polymorphisms
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compared to negative controls and we observed that genetic
variation was greater in promoters with the greatest activity. In
particular, the third of promoters with the highest activity (.5 fold
above the control vector) had significantly greater p values than
the third of promoters with the lowest activity (,2 fold above the
control vector) (Figure 4B). Intermediate activity promoters had
intermediate p values. These results were also mirrored in a
greater average number of polymorphisms per promoter (5) for the
promoters with high activity than for those with low activity (2.7).
SNPs in the proximal promoter may alter expression levels of the
transporters by affecting the rate of transcription. We used publicly
available data for gene expression in immortalized lymphoblastoid
cell lines derived from the individuals in the HapMap cohort [29],
and correlated these with genotype data for the same individuals.
Notably, out of a total of 46 common (MAF.5%) SNPs that were
observed both in our study cohort and in the populations sampled in
the HapMap project, five SNPs were significantly associated with
altered levels of transporter expression in lymphoblastoid cell lines
(Table S7). This resulted in a significantly higher frequency (11% of
the interrogated SNPs) compared to the frequency of associations at
the same significance level when all HapMap SNPs in a 650,000 bp
range surrounding the same transporters was considered (3%).
Discussion
Proximal promoters of membrane transporter genes
have a high degree of variation
A strength of this study compared to genome-wide genotyping
efforts such as the HapMap project, is that the complete
resequencing of 107 membrane transporter promoters allowed
polymorphism discovery that was unbiased by previous knowl-
edge. In contrast, the HapMap project aimed to characterize the
entire human genome, at the expense of having lower coverage of
Figure 2. Location of nucleotide diversity in transporter promoters relative to the transcription start site. Nucleotide diversity was
estimated using the mutation parameter (h) and the average heterozygosity per site parameter (p), in a 100 bp sliding window. The diversity
parameters are plotted as functions of the center of the sliding window. Blue line: African Americans; red line: European Americans; gold line: Mexican
Americans; green line: Asian Americans; and black line: combined population.
doi:10.1371/journal.pone.0006942.g002
ABC/SLC Promoter Polymorphisms
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variation in the upstream regions of membrane transporter genes
including both the proximal promoters (2250 bp to +50 bp) and
the 59 flanking regions. Based upon population genetic analysis,
this variation was higher than variation reported previously in the
coding region or flanking intronic regions of a subset of these
membrane transporter genes [10]. It might be expected that the
loci that contain a proximal promoter would be less likely to
accumulate polymorphisms and for polymorphisms in this region
to have relatively low minor allele frequencies due to functional
constraint. However, many membrane transporter promoters not
only have a high number of polymorphisms, but many of these
polymorphisms also have high minor allele frequencies. One
explanation for this is that the actual proximal promoter, which
binds the transcriptional machinery, may be small and may vary
depending upon the gene. For example, in 45 human genes,
Cooper et al observed that, on average, the maximal promoter
activity assessed in reporter assays occurred between 2250 and
2350 bp upstream of the transcriptional start site [11]. This
region may represent a true basal or proximal promoter. Notably,
this region coincides with a region of low variation in the sliding
window analysis of p and h in our study, which may contain
important functional sites (Figure 2). An alternative explanation is
that polymorphisms in regulatory regions may be altering the
expression of genes and that this altered expression may be
contributing to human evolution in some cases [31].
Promoter polymorphisms may alter gene expression
Polymorphisms in cis-regulatory regions have been shown to alter
phenotypic traits in many species including humans. Some examples
in humans include malaria resistance and lactase persistence [31].
SNPs in the promoters of transporters have been shown to associate
with altered expression levels. For example, Poonkuzhali et al
described novel SNPs in the ABCG2 promoter region (-15994C.T
(rs7699188), -56846A.C, and -15622C.T) that were significantly
associated with ABCG2 expression in lymphoblast, liver and/or
intestine tissues, and one of these was moderately associated with
clearance of the anticancer drug, imatinib [32]. We have also
identified SNPs in this study that cause altered promoter activity in
reporter assays. For example, the nucleoside transporter, SLC28A2,
has five SNPs in its proximal promoter, and the minor allele of one of
these (rs2413775 MAF$20% in all four populations) was associated
with increased luciferase activity in cell lines and in in vivo injections of
the reporter construct into mouse liver [13]. The carnitine transporter,
SLC22A5, has six SNPs in its proximal promoter. The G allele of
rs2631367 is associated with higher luciferase activity and expression
levels in lymphoblastoid cell lines. The G allele is monomorphic in
Asians and has an allele frequency between 50–60% in the other three
populations. This allele contributes to observed ethnic differences in
expression level of the transporter in lymphoblastoid cell lines [14].
Additional polymorphisms observed in this study may regulate
expression levels of transporters and could provide an explanation
for some variability observed in drug disposition.
Some proximal promoters of membrane transporters
show signs of positive selection
The signature of positive and negative selection is the high
number of rare variants as opposed to common ones [33]. Many
mutations in loci experiencing negative selection, such as coding
regions, do not increase in frequency because they do not increase
fitness. In contrast, for loci experiencing positive selection, new
mutations do increase fitness and rise in frequency until the
ancestral allele is reduced to a low frequency. For most of the
promoters in our study, there was no evidence for either positive or
negative selection, as assessed by both Tajima’s D and Fay and
Wu’s H statistics (Table S3). However, for some promoters, the
ancestral allele (defined as the allele shared between human and
chimpanzee) was rare, indicating that there is a positive selection
pressure on the derived, human-specific allele. These data suggest
that mutations in the proximal promoters are often neutral and
sometimes advantageous. This is in contrast to the coding regions
of membrane transporters, which were previously shown to have
low values of p and negative D values, indicative of negative
selection pressure [10]. This suggests that new mutations in the
promoter regions of membrane transporters are less likely to be
disadvantageous than mutations in the coding regions.
The observation of positive selection in membrane transporter
promoters is consistent with previous findings. Positive selection
was observed in some proximal promoters in human specific and
primate specific transcription factor binding sites in a genome wide
analysis of Hap Map and Perlegen SNPs [21] and has also been
found in genes involved in brain activity and in nutrient
homeostasis [22]. In this study, of the promoters that had
significant H values in at least two populations, several encoded
transporters involved in neural function and nutrient disposition
(e.g., sodium neurotransmitter symporters and proteins involved in
the transport of fatty acids, vitamin B1, and cyclic nucleotides).
One of the transporters, SLC6A4, encodes the serotonin trans-
porter, SERT. This transporter is responsible for the re-uptake of
serotonin into pre-synaptic neurons and is the target of many
clinically used anti-depressants [34]. A promoter variant in this
transporter found upstream of the region that we analyzed has
been associated with many clinical phenotypes including depres-
sion and suicide [35]. Polymorphisms in the cis-regulatory regions
Figure 3. Nucleotide diversity in transporters expressed in
human liver and/or kidney. Transporters were included in the
analysis if expressed in the top one-third of all assessed probes in mRNA
microarray experiments, or if significantly expressed in real time PCR
experiments (See Materials and Methods). A list of the transporters is
provided as Table S5. Nucleotide diversity is shown for the proximal
promoter (black bars) and the 59 flanking region (open bars).
doi:10.1371/journal.pone.0006942.g003
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dispersal behavioral in macaques [31]. Our finding that this and
another SLC6 family neurotransmitter transporter is under
positive selection is consistent with the rapid evolution of the
human brain. It is also interesting that SLCO1A2 (OATP1A2), the
transporter whose promoter exhibited the highest degree of
positive selection in all four populations, is found in the blood
brain barrier [36]. This transporter is thought to play a role in the
regulation of thyroid hormone levels in the brain and in the CNS
levels of various other endogenous compounds and xenobiotics.
Proximal promoters of liver transporters show greater
variation than those of kidney transporters
We observed greater variation in the proximal promoters of
transporters expressed primarily in the liver in comparison to those
expressed primarily in the kidney. These results suggest that the
promoter regions of transporters expressed primarily in the kidney
are under more selective pressure than those of transporters
expressed primarily in the liver. One explanation may be that
many liver transporters are known to be highly inducible and thus
are associated with a wide range of expression levels in human
liver [37]. Selective pressure against variants in the proximal
promoter region, which could potentially result in altered
expression levels, may be low. In contrast, kidney transporters
are generally not as inducible as liver transporters, and there may
be more selective pressure against genetic variation in their
promoter regions that result in variation in the expression levels of
the transporters. High genetic variation in the promoter regions of
liver transporters may thus contribute to the well-recognized wide
inter-individual variation in hepatic drug clearance, which is much
greater than variation in renal drug clearance [38]. Our results
Figure 4. A. Reporter activity of proximal promoter constructs in human cell lines. The proximal promoters were amplified from human
genomic DNA and cloned into pGL-4 gene expression vectors. Luciferase activity was measured 24 h after transfection of a panel of human cell lines.
Promoter activity is expressed as log2 [(1+ Firefly luciferase/Renilla luciferase)/Average of the negative control]. Promoters were classified as having high,
intermediate or low activity if the average relative activity across multiple cell lines was above 4, between 2 and 4, or below 2, respectively. B.
Nucleotide diversity in high, intermediate and low activity promoters.
doi:10.1371/journal.pone.0006942.g004
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regulatory mechanisms that influence the rate of transcription of
transporters expressed primarily in the liver than those expressed
primarily in the kidney. While the proximal promoter regions
examined in these liver expressed genes may be sufficient to
control expression, they may not be the only promoter regions
responsible for the overall control of hepatic expression levels. A
majority of human genes have been shown to contain multiple
alternative promoters [11,12]. This has been proposed as a
physiological mechanism to dynamically regulate expression levels
of transporters and other genes depending on the tissue and on
external stimuli [11,12,39,40], and could allow for variation in the
proximal promoter regions without significant detrimental changes
in overall expression.
Strong promoters show greater variation than weak
promoters
One of the most interesting observations in this study was that
promoters showing high activity in luciferase reporter gene assays
had significantly more variation than promoters with intermediate
or low activity (Figure 4B). Though speculative, it is possible that
strong promoters may be able to tolerate mutations that result in
moderately reduced or increased activity, because their transcrip-
tional activity would still be sufficient to maintain functional
expression levels. In contrast, weak promoters may not be able to
tolerate mutations that result in reduced activity, since even minor
decreases in promoter activity could result in deleteriously low
transcriptional rates and expression levels of these genes. Although
it cannot be ruled out that the weak promoters do not represent
the true proximal promoters of these genes due to prediction
errors, we deem it unlikely that random prediction errors would
result in the trend seen in Figure 4B. It is also possible that the
weak promoters may rely on additional enhancer elements
upstream of the regions cloned into the expression system.
Transcription factor binding sites and DNA motifs that direct
tissue specific expression are often found further upstream than
250 bp from the transcription start site [41]. These regions may
have comparable levels of genetic variation as the strong proximal
promoters. Nevertheless our experimental results suggest that most
of the loci that we sequenced do drive transcriptional activity in
cell lines. The observed alleles can be tested for their effects on
expression and eventually on drug response. Ultimately, investi-
gation of the alleles discovered in this study may improve the safety
and efficacy of commonly used pharmaceuticals.
Conclusions
In summary, we resequenced the promoters of 107 membrane
transporters in ethnically diverse populations. We detected a total
of 579 polymorphisms, and 369 SNPs had not been reported
previously. On average, variation was found to be higher in SLC
than in ABC transporters, and in transporters highly expressed in
the liver than in kidney-specific transporters. The function of a
subset of the promoters was experimentally verified in a reporter
system, and promoters with more genetic variation were shown to
have higher activity than had less variable promoters regions.
Materials and Methods
Ethics Statement
Written informed consent was obtained from all individuals who
provided their DNA for this study. The collection of these samples
was approved by UCSF’s Committee on Human Research (CHR
approval # H531-17912-09B).
Variant Identification
Study Subjects. Sequenced subjects are a subset of the
SOPHIE cohort representing ethnically diverse populations in the
San Francisco Bay Area. Subjects are healthy,18–40 year old
males and females. Subjects have four grandparents from the
population they identify with (African American, Caucasian,
Chinese, and Mexican). Subjects were recruited from the Bay Area
via flyers and on-line postings and several sites in San Francisco
These sites include the Community Health Network of San
Francisco, San Francisco General Hospital (SFGH), local
churches, colleges and community organizations such as La
Clinica de La Raza Oakland, Fair Oaks Clinic Redwood City,
Health & Environment Resource Center (HERC) Bayview,
Hunters Point, and SFGH GCRC. Subjects self-reported as
healthy, non-smokers, non-excessive alcohol drinkers (,2 drinks/
day), and are not on chronic medications. The SOPHIE cohort
includes 194 African Americans, 150 Mexican Americans, 178
Chinese Americans, and 264 Caucasian. DNA was extracted from
frozen blood samples and stored at 280uC until use.
Sequencing. Genomic DNA from 272 subjects was
sequenced. Sixty-eight subjects each of African American (41
female/27 male), Caucasian (34 female/34 male), Chinese (44
female/24male), and Mexican (49 female/19 male) descent make
up the sequenced panel. PCR primers were designed to include
250 bp upstream and 50 bp downstream of the transcriptional
start site of the RefSeq gene listed in the UCSC database. Primers
were designed using Primer 3 (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi). There were two general methods for
PCR. The first protocol used 4 ng genomic DNA in a10 ml
reaction composed of 1 ml of 10Xbuffer, 0.7 ml of MgCl2(50 mM),
0.4 ml of dNTP (2.5 mM), 0.03 ml of Platinum taq (5 U/ml), 2 ml
of Forward primer(1 mM), and 2 ml of Reverse primer(1 mM) with
cycling conditions of 95uC for 2 min, 35 cycles of 92uC for 10 sec,
60uC for 20 sec, 72uC for 1 min, after the end of the 35 cycles
followed by a 10 min hold at 72uC. The second protocol used 8 ng
genomic DNA in 10 ml reaction composed of 1 ml of Buffer, 2 ml
of Q-mix, 0.4 ml of dNTP (2.5 mM), 0.06 ml of Qiagen Taq
polymerase, 2 ml of Forward primer (2 mM), 2 ml of Reverse
primer (2 mM) (Buffer, Q-Mix, and enzyme are from Qiagen hot
start kit) with cycling conditions of 95uC for 15 min, 35 cycles of
94uC for 1 min, 60uC for 1 min, 72uC for 1 min, after end of the
35 cycles followed by a 10 min hold at 72uC. PCR and sequencing
primers in addition to annealing temperature are listed in Table
S8. Purified PCR products were sequenced in one direction using
ABI PRISM BigDye terminator sequencing Version 3.1 and an
ABI Prism 3730 DNA analyzer. The 12 ml sequencing reaction
was composed of 2.5 ml of ExoSapped PCR product, 4.5 mlo f
sequencing primer (1 mM), 1 ml BigDyeV3.1, 2 ml of 5X buffer,
and 2 ml water. Cycling conditions were 96uC for 2 min, 25 cycles
of 96uC for 15 sec, 50uC for 1 sec, 60uC for 4 minutes. DNA
sequence files were imported into and scored with
SEQUENCHER (Gene Codes, Ann Arbor, MI) Due to
technical difficulties the following promoters were missing more
than 20 bp of the target region: ABCA3, ABCB5, ABCB6, ABCD2,
SLC6A9, SLC9A3, SLC17A8, SLC22A14, SLC32A1, SLCO5A1, and
SLCO6A1.
Error Analysis. HWE tests were performed for each
polymorphism within each population. Due to the large number
of tests (1194) a HWE p-value cutoff of 0.01 was used. In most
cases only one polymorphism in one population in an amplicon
had a HWE p-value below 0.01. Twenty-seven polymorphisms
had HWE p-values below this threshold in one population
excluding the following promoters. Six promoters had multiple
polymorphisms that failed HWE tests. Five promoters (ABCF3,
ABC/SLC Promoter Polymorphisms
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homozygosity, especially in the Chinese samples. One promoter
(SLCO6A1) had an excess of heterozygotes. Polymorphisms in
ABCF3 did not pass HWE equilibrium even though PCR and
sequencing was preformed with two different primer sets. Eight
percent of promoters were double scored; no major discrepancies
were found and no additional polymorphisms were observed.
Functional Characterization of Promoters
Construction of the membrane transporter promoter
region. To construct the reporter plasmids containing the
proximal promoter regions of the membrane transporters, we
used Primer 3 (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi) to design primers by inputting 500 bp of
upstream and 100 bp downstream sequence relative to the
predicted transcription start site (TSS) of the gene. These
regions were amplified by a PCR of human genomic DNA
using the touchdown PCR protocol [17] or other PCR protocols
reported previously by our group [13,14]. The primers used to
construct the membrane transporter promoter regions are listed in
Table S9. The amplified promoter fragments were digested with
the appropriate restriction enzymes (New England Biolabs) and
cloned into the reporter gene expression vector pGL-4 (Promega),
which contains a Firefly luciferase reporter gene downstream from
the multiple cloning site.
Cell culture, transient transfections, and luciferase
activity assays. Similar protocols were used for determining
the activity of ABC and SLC transporter promoters. For the ABC
transporters, the constructs were transiently transfected into
HepG2, PANC-1, HCT-116, JEG-3 and T98 cells, using a
previously reported transfection protocol [17]. These cell lines
were purchased from the American Type Culture Collection
(Manassas, VA). A slightly modified protocol, described in detail in
Tahara et al. and Yee et al., was used to transfect the SLC
transporter proximal promoter constructs into HepG2, HCT-116
and ACHN cells. ACHN cells were purchased from the American
Type Culture Collection (Manassas, VA) and the HepG2 and
HCT-116 were supplied by the Cell Culture facility (University of
California San Francisco). Briefly, 24 hours after transfection the
cells were assayed for luciferase activity in a PE Wallac
Luminometer
TM (Perkin Elmer) or GloMax 96 Microplate
Luminometer (Promega) using the Dual-Glo
TM Luciferase Assay
System (Promega) according to the manufacturer’s instructions.
For normalization of the data between cell types, the relative
promoter activities were expressed as log2 [(1+ Firefly luciferase/
Renilla luciferase)/Average of the negative control] [11].
Association of Variants with Transporter Expression
Levels
SNPs found both in our study populations and in the HapMap
dataset (Phase II, release 23) were associated with transporter
mRNA expression levels in lymphoblastoid cell lines derived from
the 210 unrelated HapMap individuals [29]. Genotype data were
downloaded from the HapMap website (http://www.hapmap.
org), and normalized expression data from http://www.sanger.ac.
uk/humgen/genevar/. This data has been deposited in the
MIAME database with accession number GSE6536. Associations
were calculated using PLINK v1.04 [42] (http://pngu.mgh.
harvard.edu/purcell/plink/) for 46 common SNPs (MAF$5%)
that were found in both datasets, as well as for all common
HapMap SNPs located within a 650,000 bp range surrounding
the same transporter genes. A moderate nominal significance level
of p,0.01 was used to determine if significantly associated SNPs
were found at higher frequency in the sequenced promoter regions
compared to in the entire 650,000 bp range.
Population Genetic Parameters
Nucleotide diversity was estimated using the mutation param-
eter (h; Eq. 1) and the average heterozygosity per site parameter
(p; Eq. 2) (Tajima, 1989), assuming an infinite sites neutral
mutation model:
^ h h~
S
Pn{1
i~1
1
i
ð1Þ
^ p p~
n
n{1
X S
i~1
2piqi ð2Þ
where S is the number of segregating sites, n is the number of
chromosomes analyzed and pi and qi are the frequencies of the
non-ancestral and ancestral alleles, respectively. Both measures
were normalized for the number of bases sequenced. Two different
test statistics were used to assess deviations from the variation
patterns expected under the neutral mutation model: Tajima’s D
[43] statistic was calculated as the normalized difference between
the p and h statistics, and Fay and Wu’s H statistic [33,44] was
calculated as the difference between p and hH:
^ h hH~
n
n{1
X S
i~1
2p2
i ð3Þ
In the calculation of H, the chimpanzee allele (UCSC Genome
Browser Pan Troglodytes March 2006 assembly) was used as the
ancestral human allele. Variant sites were included in the analysis
only if the chimpanzee allele matched one of the determined
human alleles and the local (65 bp surrounding the variant site)
chimpanzee–human alignment was unambiguous. To assess
statistical significance, the observed values of D and H were
compared to the parameter distributions in simulated populations
having the corresponding number of chromosomes and segregat-
ing sites. Ten thousand simulations were performed for each
sequenced region using the ms software [45] under the
conservative assumption of no recombination. The proportion of
simulated H or D parameters with more extreme values than those
observed corresponds to the hypothesis test p-value.
Nucleotide diversity was calculated for each transporter
individually, as well as for various groups of genes (e.g., ABC
transporters, SLC transporters, transporters highly expressed in
the liver and/or the kidney, transporters with high or low
promoter activity in in vitro assays). For each transporter/group of
transporters, parameters were calculated for the proximal
promoter region (+50 to 2250 bp surrounding the transcription
start site), the 59 flanking sequence, and the entire sequenced
regions.
To determine the distribution of genetic variation relative to the
transcription start sites, h and p were calculated in a 100 bp sliding
window and plotted against the position of the window center
(Fig. 2). The results were robust for changes in window size (20, 50,
100, and 200 bp windows were examined). The promoter regions
of 5 genes (ABCC2, SLC29A1, SLC28A2, SLC7A5, and SLC13A1)
were sequenced in a similar but separate set of individuals within
the SOPHIE cohort. To enable comparisons within the same
ABC/SLC Promoter Polymorphisms
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of population genetics statistics.
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